Bone mass and long-term monophasic oral contraceptive treatment in young women

Franco Polatti, Francesca Perotti, Nadia Filippa, Davide Gallina, Rossella E. Nappi

Research output: Contribution to journalArticlepeer-review


A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

Original languageEnglish
Pages (from-to)221-224
Number of pages4
Issue number4
Publication statusPublished - 1995


  • alkaline phosphatase
  • bone mass density
  • monophasic contraceptive
  • urinary excretion

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine
  • Medicine(all)


Dive into the research topics of 'Bone mass and long-term monophasic oral contraceptive treatment in young women'. Together they form a unique fingerprint.

Cite this